Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic GLP-1 that stimulates insu.lin secretion. 
Marketed under the brand name Victoza,Liraglutide is an injectable developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing Liraglutide in the U.S. and E.U. under the brand name  as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

Function of Liraglutide
 

Common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.
 

BENEFITS OF GLP-1 AGONISTS
 --Helps slow food leaving your stomach
 --Helps prevent your liver from making too much sugar
 --Helps the pancreas produce more insul when your blood sugar levels are high
 --Can help control blood glucose
 --Can reduce hyperglycemia, especially after meals
 --Can reduce fasting insul and fasting glucose
 --Can reduce hemoglobin A1c
 --Can decrease appetite and caloric intake, while inhibiting weight gain
 --Has been shown to lower triglyceride levels and oxidative stress from high LDL
 --Has been shown to help induce weight loss in obese patients with higher dosing
 --Helps decrease leptin and increase leptin sensitivity
 --Can increase the conversion of white fat to brown fat